Agni-01 and cytoDRiVE® data at #AACR 2025

Circulogene Expands Solid Tumor Genomic Capabilities with Launch of OncoGenDx Tissue Assay https://lnkd.in/gAJCQqEf PENSACOLA, Fla., Oct. 7, 2025 /PRNewswire/ — Circulogene today announced the national launch of OncoGenDx, an innovative tissue-based comprehensive genomic profiling (CGP) assay that delivers expanded insights into all solid tumors. Designed to complement Circulogene’s [...]

Imagion Biosystems has reached a major milestone with the completion of manufacturing its MagSense® HER2 Breast Cancer imaging agent for the upcoming Phase 2 clinical trial. The company’s collaboration with Siemens Healthineers and Wayne State University is helping refine AI-based imaging protocols to improve accuracy and reduce dosage needs. With the FDA IND submission planned for later this year, and a successful AU$3.5 million capital raise, Imagion is moving closer to bringing advanced, non-radioactive molecular imaging to patients. This progress marks another strong step toward earlier and more precise cancer detection. https://lnkd.in/gtHwCyev #HealthcareInnovation #CancerResearch #MedicalImaging #Biotech #ASX #kapitalesresearch

After charting over 70 tumor targets from discovery to mid-stage trials, we’ve reached the nucleus. 𝘑𝘰𝘶𝘳𝘯𝘦𝘺 𝘵𝘰 𝘵𝘩𝘦 𝘕𝘶𝘤𝘭𝘦𝘶𝘴 concludes with 10 Phase 3 clinical trials. A closer look at the late-stage landscape reveals key themes: 🔹 #PSMA and #SSTR 2/3 dominate, accounting for all 10 trials. 🔹 #Lu177 and #Ac225 are leading the charge. 🔹 Modalities are expanding: peptides, antibodies, and small molecules are all represented. The balance between beta and alpha emitters signals a maturing, yet diversifying, approach to RLT strategy, and the modality mix reflects an evolution in both molecular design and delivery precision. As we reach the nucleus, we also mark the starting point of potential transformation for patients. Where the map goes next is up to all of us. As always, for the interactive version, please visit https://hubs.ly/Q03MN70z0. #RLT #Radiopharmaceuticals #TumorTargets #JourneytotheNucleus #Oncology

This week at #ESGCT2025, T-knife Scientist Mira Heichenko presented preclinical data showcasing our MyT™ platform as a powerful engine for discovering high-affinity, next-generation TCR-T therapies for solid tumors.   By combining computational multi-omics workflows with our proprietary humanized in vivo screening, we identified highly immunogenic solid tumor antigens not previously recognized as functional.   We’re excited to advance our lead candidate, TK-6302, a supercharged PRAME T cell receptor therapy, with a Clinical Trial Application (CTA) planned for this year.   Learn more: https://lnkd.in/gcrBqYvp

⭐ We're excited to announce the general availability of Atlas H&E-TME, our AI-powered application for comprehensive tumor microenvironment profiling in H&E images. After successful early access pilots with our existing academic and biopharma partners, Atlas H&E-TME is now being made available to new biopharma partners to unlock deeper insights from routine H&E slides—without specialized staining or multiplexing. What does Atlas H&E-TME deliver? ✔️ Robust analyses in hours, not days  ✔️ Visual overlays for 7 tissue types and 9 cell classes ✔️ Over 5,000 quantitative metrics ✔️ Validated, generalizable results across primary and metastatic sites Built using Atlas, the foundation model we co-developed with Mayo Clinic and Charité - Universitätsmedizin Berlin, Atlas H&E-TME addresses a critical bottleneck in cancer research by delivering results with the speed, accuracy, and scale needed to advance precision oncology. 📰 Read the full press release here: https://lnkd.in/eeagvNBA 👉 Click here to learn about how you can get a free trial: https://lnkd.in/eqbrjkNC

CAPS Medical’s PlasmaSure™ Receives FDA Breakthrough Device Designation https://lnkd.in/gV4PxN-K Breakthrough designation for Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) supports CAPS Medical’s mission to transform tumor ablation into a simple, selective, and in-office procedure SANTA MONICA, Calif. and NETANYA, Israel, Oct. 15, 2025 /PRNewswire/ [...]

What if you could elucidate a broader landscape of #cancer biology to identify actionable new drug targets and novel diagnostic, prognostic, and predictive biomarkers? Sapient's 𝐓𝐮𝐦𝐨𝐫 𝐏𝐫𝐨𝐭𝐞𝐨𝐦𝐢𝐜𝐬 method enables deep characterization of more than 12,000 proteins in tumors, including cell surface and intracellular proteins, and their PTMs and proteoforms. See how our DynamiQ™ tumor and tissue database can further enable your studies to identify those that are differentially expressed between tumor and normal tissue. Request a study: https://lnkd.in/gHSsin95 #tumorproteomics #tumors #oncology

💡 Next-Generation Nanoplatforms for SN-38 Delivery in Cancer Therapy In their recent publication in Journal of Controlled Release (2025), Mercedes Lozano-Garcia and colleagues present an in-depth review of multifunctional nanoplatforms and delivery strategies for SN-38, the potent active metabolite of irinotecan. Although SN-38 is up to 1,000 times more potent than irinotecan, its poor solubility and instability have limited its clinical use. The study explores advanced delivery approaches—including nanoparticles, dendrimers, prodrugs, and lipid-based carriers—that enable targeted, tumor-responsive, and controlled drug release while minimizing systemic toxicity. Emerging multifunctional systems that combine targeting ligands, stimuli-responsive components, and imaging elements hold great promise for achieving safer, more effective chemotherapy—though challenges remain in biocompatibility, scalability, and clinical translation. https://lnkd.in/eVBwcQBJ #CancerTherapy #Nanomedicine #DrugDelivery #SN38 #Irinotecan #Nanotechnology #OncologyFrontier #MediaMedic #JournalofControlledRelease

Tuning ECM cross-links and fibronectin composition reveals new levers for cancer adhesion In Acta Biomaterialia, Yang et al. built biomimetic hydrogels using FibriCol® collagen I and plasma fibronectin (pFN) from Advanced BioMatrix. By adding TG2 cross-links, they showed how fiber structure and matrix composition work together to regulate ovarian cancer cell adhesion. This work underscores that collagen–fibronectin balance and cross-linking aren’t just structural—they directly shape cell behavior. Such defined ECM models offer sharper tools for screening assays, invasion studies, and tumor-microenvironment engineering. Read the full paper here: https://lnkd.in/gafsMMqp #ECM #FibriCol #Fibronectin #CancerModels #ScreeningAssays #AdvancedBioMatrix

CAPS Medical’s PlasmaSure™ Receives FDA Breakthrough Device Designation https://lnkd.in/gV4PxN-K Breakthrough designation for Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) supports CAPS Medical’s mission to transform tumor ablation into a simple, selective, and in-office procedure SANTA MONICA, Calif. and NETANYA, Israel, Oct. 15, 2025 /PRNewswire/ [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News